https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14877 Sat 24 Mar 2018 08:22:24 AEDT ]]> Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5045 Sat 24 Mar 2018 07:45:38 AEDT ]]>